{
    "topic": "coronavirus",
    "source": "The Daily Caller",
    "bias": 2,
    "url": "https://dailycaller.com/2020/03/18/hydroxychloroquine-coronavirus-covid19-cure-study/",
    "title": "Clinical Trial Raises Hopes That Malaria Drug Could Be Coronavirus Cure",
    "date": "2020-03-18",
    "authors": "",
    "content": "A drug used to treat malaria is showing promise in lab and clinical studies for coronavirus , leading to reserved enthusiasm for some scientists .\nFrench researchers found that hydroxychloroquine lowered virus levels in most patients who took part in a clinical study this month .\nPresident Donald Trump asked his coronavirus task force about the drug during a briefing on Wednesday .\nThe results of a clinical trial in France and studies conducted in lab settings are building hope that a drug usually used to treat malaria and arthritis can treat and possibly cure coronavirus patients , though scientists say more data is needed before drawing a firm conclusion .\n\u201c It has a lot of potential , though we \u2019 re not going on a lot of data yet , \u201d Dr. Peter Hotez , the dean for the National School of Tropical Medicine at the Baylor School of Medicine , said of early studies of hydroxycholoroquine , a malaria drug developed in the 1940s .\nPresident Donald Trump asked the White House \u2019 s coronavirus task force about possibly using the drug , task force coordinator Dr. Deborah Birx said Wednesday .\nBirx said that the drug is being studied \u201c very carefully , \u201d as are several other potential therapeutics .\nOn Tuesday , a team of French scientists released the first results of a clinical study of the use of hydroxychloroquine on 24 coronavirus patients from southeast France .\nThe research team , led by Didier Raoult , a renowned infectious disease expert from l \u2019 Institut Hospitalo-Universitaire in Marseille , administered the drug for 10 days along with azithromycin , a common antibiotic .\nResearchers said the drugs cleared the virus in the nose and throat of most observed patients in three to six days . The study found that after six days of treatment , 70 percent of patients administered hydroxychloroquine were clear of the virus , compared to just 12.5 percent of patients who were not given drugs . ( RELATED : Fauci On Coronavirus In US : \u2018 It \u2019 s Going To Get Worse \u2019 )\nAzithromycin boosted the effect of hydroxychloroquine , according to the study . After six days of treatment , all patients treated with the drug combination \u201c were virologically cured , \u201d compared to 57.1 percent of patients treated with hydroxycholorquine by itself .\n\u201c We therefore recommend that COVID-19 patients be treated with hydroxychloroquine and azithromycin to cure their infection and to limit the transmission of the virus to other people in order to curb the spread of COVID-19 in the world , \u201d wrote researchers , who acknowledged the small sample size of the study .\nLab studies have shown that hydroxychloroquine , which was developed in the 1940s , inhibited coronavirus . A study published in Cell Discovery on Wednesday by three Chinese scientists found that hydroxychloroquine inhibited coronavirus in vitro , or in a lab culture .\nHotez , the infectious disease expert , told \u2588\u2588\u2588 News Foundation he was \u201c enthusiastic \u201d about early results of studies involving hydroxychloroquine , though he said more data is needed to determine if the drug can effectively treat coronavirus .\n\u201c We urgently need to accelerate new antimicrobial therapies . If hydroxychloroquine could be approved in therapy it would be a game-changer , \u201d Hotez said .\n\u201c The important next step is to show that it has an impact on reducing severity of symptoms in clinical disease . \u201d\nHotez said that an ideal study would be conducted in areas with high rates of transmission , such as the Lombardy region in Italy .\nMore clinical trials are underway . A researcher at Asan Medical Center , a top research hospital in South Korea , is conducting a clinical trial of 150 patients with mild cases of coronavirus . The lead researcher , Sung-Han Kim , estimates that the trial will be completed in May .\nAccording to NBC News , French drug maker Sanofi is working with health authorities to study whether hydroxychloroquine can help with coronavirus . The company is encouraged by preliminary findings , according to NBC News , but still does not have enough data to determine its efficacy .\nHealth officials in Belgium and South Korea have recommended the use of hydroxychloroquine patients displaying either severe or mild symptoms from COVID-19 , the disease caused by coronavirus .\nThe United Kingdom appears to have some hope for the drug . On Sunday , government officials there banned the export and hoarding of hydroxychloroquine and two other drugs that could be useful as therapeutics , according to Pharmaceutical Technology .",
    "content_original": "A drug used to treat malaria is showing promise in lab and clinical studies for coronavirus, leading to reserved enthusiasm for some scientists.\n\nFrench researchers found that hydroxychloroquine lowered virus levels in most patients who took part in a clinical study this month.\n\nPresident Donald Trump asked his coronavirus task force about the drug during a briefing on Wednesday.\n\nThe results of a clinical trial in France and studies conducted in lab settings are building hope that a drug usually used to treat malaria and arthritis can treat and possibly cure coronavirus patients, though scientists say more data is needed before drawing a firm conclusion.\n\n\u201cIt has a lot of potential, though we\u2019re not going on a lot of data yet,\u201d Dr. Peter Hotez, the dean for the National School of Tropical Medicine at the Baylor School of Medicine, said of early studies of hydroxycholoroquine, a malaria drug developed in the 1940s.\n\nPresident Donald Trump asked the White House\u2019s coronavirus task force about possibly using the drug, task force coordinator Dr. Deborah Birx said Wednesday.\n\nBirx said that the drug is being studied \u201cvery carefully,\u201d as are several other potential therapeutics.\n\nOn Tuesday, a team of French scientists released the first results of a clinical study of the use of hydroxychloroquine on 24 coronavirus patients from southeast France.\n\nThe research team, led by Didier Raoult, a renowned infectious disease expert from l\u2019Institut Hospitalo-Universitaire in Marseille, administered the drug for 10 days along with azithromycin, a common antibiotic.\n\nResearchers said the drugs cleared the virus in the nose and throat of most observed patients in three to six days. The study found that after six days of treatment, 70 percent of patients administered hydroxychloroquine were clear of the virus, compared to just 12.5 percent of patients who were not given drugs. (RELATED: Fauci On Coronavirus In US: \u2018It\u2019s Going To Get Worse\u2019)\n\nAzithromycin boosted the effect of hydroxychloroquine, according to the study. After six days of treatment, all patients treated with the drug combination \u201cwere virologically cured,\u201d compared to 57.1 percent of patients treated with hydroxycholorquine by itself.\n\n\u201cWe therefore recommend that COVID-19 patients be treated with hydroxychloroquine and azithromycin to cure their infection and to limit the transmission of the virus to other people in order to curb the spread of COVID-19 in the world,\u201d wrote researchers, who acknowledged the small sample size of the study.\n\nLab studies have shown that hydroxychloroquine, which was developed in the 1940s, inhibited coronavirus. A study published in Cell Discovery on Wednesday by three Chinese scientists found that hydroxychloroquine inhibited coronavirus in vitro, or in a lab culture.\n\nHotez, the infectious disease expert, told The Daily Caller News Foundation he was \u201centhusiastic\u201d about early results of studies involving hydroxychloroquine, though he said more data is needed to determine if the drug can effectively treat coronavirus.\n\n\u201cWe urgently need to accelerate new antimicrobial therapies. If hydroxychloroquine could be approved in therapy it would be a game-changer,\u201d Hotez said.\n\n\u201cThe important next step is to show that it has an impact on reducing severity of symptoms in clinical disease.\u201d\n\nHotez said that an ideal study would be conducted in areas with high rates of transmission, such as the Lombardy region in Italy.\n\nMore clinical trials are underway. A researcher at Asan Medical Center, a top research hospital in South Korea, is conducting a clinical trial of 150 patients with mild cases of coronavirus. The lead researcher, Sung-Han Kim, estimates that the trial will be completed in May.\n\nAccording to NBC News, French drug maker Sanofi is working with health authorities to study whether hydroxychloroquine can help with coronavirus. The company is encouraged by preliminary findings, according to NBC News, but still does not have enough data to determine its efficacy.\n\nHealth officials in Belgium and South Korea have recommended the use of hydroxychloroquine patients displaying either severe or mild symptoms from COVID-19, the disease caused by coronavirus.\n\nThe United Kingdom appears to have some hope for the drug. On Sunday, government officials there banned the export and hoarding of hydroxychloroquine and two other drugs that could be useful as therapeutics, according to Pharmaceutical Technology.\n\nContent created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact licensing@dailycallernewsfoundation.org.",
    "source_url": "www.dailycaller.com",
    "bias_text": "right",
    "ID": "gYk8NiwvQWms2kyY"
}